Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

Détails

ID Serval
serval:BIB_4E0C4E1AA94B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.
Périodique
Science
Auteur⸱e⸱s
Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., Hunziker T., Saurat J.H., Tschopp J., French L.E.
ISSN
0036-8075 (Print)
ISSN-L
0036-8075
Statut éditorial
Publié
Date de publication
1998
Volume
282
Numéro
5388
Pages
490-493
Langue
anglais
Résumé
Toxic epidermal necrolysis (TEN, Lyell's syndrome) is a severe adverse drug reaction in which keratinocytes die and large sections of epidermis separate from the dermis. Keratinocytes normally express the death receptor Fas (CD95); those from TEN patients were found to express lytically active Fas ligand (FasL). Antibodies present in pooled human intravenous immunoglobulins (IVIG) blocked Fas-mediated keratinocyte death in vitro. In a pilot study, 10 consecutive individuals with clinically and histologically confirmed TEN were treated with IVIG; disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIG may be an effective treatment.
Mots-clé
Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Blocking/immunology, Antibodies, Blocking/therapeutic use, Antigens, CD95/immunology, Antigens, CD95/physiology, Apoptosis, Child, Dermis/pathology, Disease Progression, Epidermal Necrolysis, Toxic/pathology, Epidermal Necrolysis, Toxic/therapy, Epidermis/pathology, Fas Ligand Protein, Female, Humans, Immunoglobulins, Intravenous/therapeutic use, Jurkat Cells, Keratinocytes/metabolism, Keratinocytes/pathology, Male, Membrane Glycoproteins/metabolism, Middle Aged, Pilot Projects
Pubmed
Web of science
Création de la notice
24/01/2008 16:18
Dernière modification de la notice
20/08/2019 15:03
Données d'usage